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ABSTRACT
The cellular prion protein (PrPC) acts as a scaffold protein that
organises signalling complexes. In synaptosomes, the aggregation of
PrPC by amyloid-β (Aβ) oligomers attracts and activates cytoplasmic
phospholipase A2 (cPLA2), leading to synapse degeneration. The
signalling platform is dependent on cholesterol released from
cholesterol esters by cholesterol ester hydrolases (CEHs). The
activation of cPLA2 requires cholesterol released from cholesterol
esters by cholesterol ester hydrolases (CEHs), enzymes dependent
upon platelet activating factor (PAF) released by activated cPLA2.
This demonstrates a positive feedback system in which activated
cPLA2 increased cholesterol concentrations, which in turn facilitated
cPLA2 activation. PAF was also required for the incorporation of the
tyrosine kinase Fyn and cyclooxygenase (COX)-2 into Aβ–PrPC–
cPLA2 complexes. As a failure to deactivate signalling complexes can
lead to pathology, the mechanisms involved in their dispersal were
studied. PAF facilitated the incorporation of acyl-coenzyme A:
cholesterol acyltransferase (ACAT)-1 into Aβ–PrPC–cPLA2–COX-2–
Fyn complexes. The esterification of cholesterol reduced cholesterol
concentrations, causing dispersal of Aβ–PrPC–cPLA2–COX-2–Fyn
complexes and the cessation of signalling. This study identifies PAF
as a key mediator regulating the cholesterol ester cycle, activation of
cPLA2 and COX-2 within synapses, and synapse damage.
KEY WORDS: Cholesterol, Esterification, Cyclooxygenase,
Platelet-activating factor, Phospholipase A2, Synaptosome
INTRODUCTION
The cellular prion protein (PrPC) is mainly found in specific
membrane micro-domains commonly called lipid rafts (Taraboulos
et al., 1995). PrPC acts as a scaffold protein that organises signalling
complexes (Linden et al., 2012) and is associated with multiple
signalling proteins, including the tyrosine kinase Fyn (Mouillet-
Richard et al., 2000) and cytoplasmic phospholipase A2 (cPLA2)
(Bate et al., 2010), which are linked to synapse degeneration. PrPC is
concentrated at synapses (Herms et al., 1999), and the aggregation
of PrPC (Chiesa et al., 2008) or cross-linkage of PrPC with
monoclonal antibodies (mAbs) (Solforosi et al., 2004) causes
synaptic abnormalities. More recently, PrPC has been identified as a
receptor for amyloid-β (Aβ) oligomers (Laurén et al., 2009) which
are responsible for the synapse degeneration and cognitive decline
in patients with Alzheimer’s disease (AD) (Selkoe, 2002; Shankar
et al., 2008). The aggregation of PrPC mediated by Aβ oligomers
forms a signalling complex containing activated cPLA2 and leads to
synapse degeneration (Bate and Williams, 2011).
Cholesterol is a key component of lipid rafts (Brown and London,
2000) and, given that the formation and function of lipid rafts
depends upon cholesterol concentrations (Rajendran and Simons,
2005), it follows that fluctuations in cholesterol concentrations may
alter cell signalling within lipid rafts. We recently reported that
soluble Aβ oligomers, highly toxic forms of Aβ (Yang et al., 2017),
increased cholesterol concentrations in synaptosomes (West et al.,
2017). This observation is consistent with reports showing that Aβ is
concentrated in synapses (Lacor et al., 2004; Takahashi et al., 2010)
and that the concentrations of cholesterol are increased in Aβ-
positive synapses in the cortex of AD patients (Gylys et al., 2007).
The increased cholesterol concentrations are dependent upon
activated cholesterol ester hydrolases (CEHs) (West et al., 2017),
which participate in the cholesterol ester cycle that controls
membrane cholesterol concentrations (Chang et al., 2006). Thus,
CEH inhibitors block both the Aβ-induced increase in cholesterol
concentrations and Aβ-induced synapse damage in cultured
neurons. However, the mechanisms leading to the activation of
CEHs are poorly understood.
The present study investigated two key ideas. Firstly, we studied
the signalling pathways leading to activation of CEHs in
synaptosomes. The Aβ-induced activation of CEHs was
dependent upon activation of cPLA2 and the production of
platelet-activating factor (PAF). The increased cholesterol
concentrations stabilised a signalling platform containing Aβ,
PrPC, cPLA2, Fyn and cyclooxygenase (COX)-2, and led to the
production of prostaglandin E2 (PGE2). Concentrations of PGE2 are
raised in AD (Montine et al., 1999) and, in cultured neurons, PGE2
causes extensive synapse damage (Bate et al., 2010).
In addition, this study examined the dissociation of signalling
platforms as a physiological process that limits the intensity of
signalling. Acyl-coenzyme A:cholesterol acyltransferase (ACAT)-1
was incorporated into Aβ–PrPC–cPLA2–COX-2–Fyn signalling
complexes. The esterification of cholesterol by this enzyme reduced
cholesterol concentrations, leading to the dissociation of complexes
and reduced cell signalling. We hypothesise that the dissociation of
signalling complexes is a physiological process that limits the
intensity of cell activation. Consequently, conditions that prevent
the dissociation of signalling complexes may lead to sustained
activation, cell disruption and disease.
RESULTS
cPLA2 inhibitors and PAF antagonists blocked the Aβ-
induced increase in cholesterol concentrations
Aβ in the soluble fraction of extracts from AD brains (hereafter,
soluble AD brain extracts) activates synaptic CEHs, resulting in
increased cholesterol concentrations (West et al., 2017). The AD
brain extracts used in the assays of the present study contained
predominantly Aβ monomers, dimers and trimers, as shown byReceived 4 October 2017; Accepted 19 March 2018
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immunoblotting (Fig. 1A). Initially, we looked at whether AD brain
extracts affected the amounts and location of CEHs. CEHs in
synaptosomes were found to be predominantly within detergent-
resistant membranes (DRMs) (a crude measure of lipid rafts)
(Fig. 1B). Synaptosomes incubated with soluble AD brain extract
for 1 h did not have different amounts of CEHs (or caveolin, a
loading control) compared with that in synaptosomes incubated
with control medium (Fig. 1C). Because Aβ activates cPLA2
(Palavicini et al., 2017; Zhu et al., 2006), we sought to determine
whether activated cPLA2 was involved in the increased synaptic
cholesterol concentrations by using two selective cPLA2 inhibitors
[arachidonyl trifluoromethyl ketone (AACOCF3) and methyl
arachidonyl fluorophosphonate (MAFP)]. The activation of
cPLA2 is the first step in the production of bioactive lipids
[including prostaglandins (PGs) and PAF] that affect synapse
function (Clark et al., 1992; Sang et al., 2005). The addition of
soluble AD brain extract to synaptosomes increases the production
of PGE2 in an Aβ-dependent manner (West et al., 2017). Here, we
show that incubation with soluble AD brain extract also
significantly increased concentrations of PAF in synaptosomes
when compared with incubation with control medium (314±56 nM
compared with 28±8 nM, n=6, P<0.01, mean±s.d.) or with Aβ-
depleted soluble AD brain extract (314±56 nM compared with 32±
10 nM, n=6, P<0.01). The Aβ-depleted soluble AD brain extract
was prepared by incubation with mAb 4G8 (reactive with 17-24 of
Aβ), which reduced the concentrations of Aβ42 (1±0.07 nM Aβ42
compared with 0.03±0.015 nM, n=9, P<0.01) and Aβ40 (4.36±
0.22 nM Aβ40 compared with 0.24±0.07 nM, n=9, P<0.01) in AD
brain extracts. In contrast, immunodepletion with mAb 3F4
(reactive with human prion proteins) had no significant effect on
concentrations of Aβ42 (1±0.07 nM Aβ42 compared with 0.98±
0.08 nM, n=9, P=0.38) and Aβ40 (4.36±0.22 nM Aβ40 compared
with 4.15±0.28 nM, n=9, P=0.45). Pre-treatment of synaptosomes
with 1 µM AACOCF3 or 1 µM MAFP reduced the Aβ-induced
increase in PGE2 (Fig. 1D) and PAF (Fig. 1E), indicating that these
concentrations of drugs inhibited cPLA2.
Although there were no significant differences in cholesterol
concentrations between synaptosomes treated with a vehicle control
and those treated with 1 µM AACOCF3 or with 1 µM MAFP, the
Aβ-induced increase in cholesterol concentrations was reduced
in synaptosomes pre-treated with 1 µM AACOCF3 or with 1 µM
MAFP (Fig. 1F). Next, the downstream products of cPLA2 activation
were examined in more detail. Pre-treatment of synaptosomes with
inhibitors of COXs (5 µM acetyl salicylic acid or 5 µM ibuprofen),
the enzymes that metabolise arachidonic acid to PGs, did not affect
Fig. 1. PLA2 inhibitors and PAF antagonists block the Aβ-induced
increase in cholesterol concentrations. (A) Immunoblot showing forms of
Aβ in soluble AD brain extract, including monomers (M), dimers (D) and trimers
(T). (B) The amounts of CEHs in total cell membranes, DRMs and DSMs from
synaptosomes. (C) The amounts of CEHs and caveolin in synaptosomes
incubated with control medium or AD brain extract containing 1 nM Aβ42. The
concentrations of (D) PGE2 and (E) PAF in synaptosomes pre-treated with a
vehicle control or cPLA2 inhibitors (1 µM AACOCF3 or 1 µM MAFP) and
incubated with either control medium (white bars) or AD brain extract
containing 1 nM Aβ42 (black bars). Values are means±s.d. from triplicate
experiments performed three times; n=9. * indicate PGE2/PAF concentrations
significantly lower than those of synaptosomes incubated with AD brain
extract. The concentrations of cholesterol in synaptosomes pre-treated with
(F) a vehicle control or cPLA2 inhibitors (1 µM AACOCF3 or 1 µM MAFP), or
(G) PAF antagonists [1 μM H-PAF, 1 μM ginkgolide B (gink B) or 1 μM CV-
6209] as shown and incubated with control medium (white bars) or AD brain
extract containing 1 nM Aβ42 (black bars). Values are means±s.d. from
triplicate experiments performed three times; n=9. * indicate cholesterol
concentrations significantly lower than those of synaptosomes incubated with
AD brain extract. (H) The cholesterol concentrations of synaptosomes
incubated with PAF as shown. Values are means±s.d. from triplicate
experiments performed three times; n=9. * indicate cholesterol concentrations
significantly higher than those in control synaptosomes. (I) There was a
significant inverse correlation between the concentrations of cholesterol and
cholesterol esters in synaptosomes incubated with PAF (62 to 500 nM);
Pearson’s coefficient=−0.93, P<0.01. (J) The cholesterol concentrations of
synaptosomes pre-treated with a vehicle control, DEUP, or cholesteryl N-(2-
dimethylaminoethyl)carbamate and incubated with control medium (white
bars) or 500 nM PAF (black bars). Values are means±s.d. from triplicate
experiments performed three times; n=9.
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the Aβ-induced increase in cholesterol concentrations (data not
shown). In contrast, pre-treatment of synaptosomes with PAF
antagonists [Hexa-PAF (H-PAF), ginkgolide B or CV-6209]
reduced the Aβ-induced increase in cholesterol concentrations
(Fig. 1G), suggesting that PAF was a key molecule regulating
synaptic cholesterol concentrations. Further studies showed that PAF
caused a dose-dependent increase in cholesterol concentrations
(Fig. 1H). This was accompanied by reductions in cholesterol ester
concentrations in PAF-treated synaptosomes, and there was a
significant inverse correlation between the concentrations of
cholesterol and cholesterol esters (Fig. 1I). Taken together, these
results suggest that the Aβ-induced activation of cPLA2 was a
source of PAF that subsequently activated CEHs. This hypothesis
was supported by the observation that the PAF-induced increase
in cholesterol concentrations was blocked by selective CEH
inhibitors [diethylumbelliferyl phosphate (DEUP) and cholesteryl
N-(2-dimethylaminoethyl)carbamate; Fig. 1J].
Aβ caused the translocation of COX-2 to DRMs
Because PGE2 causes synapse degeneration in cultured neurons
(Bate et al., 2010), the effects of drugs that inhibit COXs, enzymes
that convert arachidonic acid to PGs, were studied. There are two
major COX isoforms, and in untreated synaptosomes both COX-1
and COX-2 were found to be predominantly within detergent-
soluble membranes (DSMs). The addition of soluble AD brain
extract, but not Aβ-depleted soluble AD brain extract, caused some
COX-2 to migrate into DRMs (Fig. 2B,C). However, the addition
had no effect on the amounts of COX-1 or caveolin in DRMs
(Fig. 2A,C). There was a significant correlation between the
amounts of COX-2 in DRMs and the concentrations of PGE2
produced by synaptosomes in response to Aβ (Pearson’s
coefficient=0.85, P<0.01; Fig. 2D). This was consistent with the
hypothesis that Aβ activates the COX-2 isoform. Cholesterol is a
major factor in the formation of DRMs (Xu et al., 2001), and there
was a significant correlation between cholesterol concentrations and
the amounts of COX-2 in DRMs in synaptosomes incubated with
Aβ (Pearson’s coefficient=0.85, P<0.01; Fig. 2E). Pre-treatment of
synaptosomes with DFU or DuP-697 (COX-2-selective inhibitors;
Copeland et al., 1994; Riendeau et al., 1997), but not valeryl
salicylate or SC-560 (COX-1-selective inhibitors; Bhattacharyya
et al., 1995; Smith et al., 1998), reduced the Aβ-induced increase in
PGE2 (Fig. 2F). Soluble AD brain extracts cause the Aβ-dependent
loss of synaptic proteins, including synapsin-1, vesicle-associated
membrane protein-1, synaptophysin and cysteine string protein,
from cultured neurons in a tissue culture model of synapse
degeneration (West et al., 2017). Here, the addition of soluble AD
brain extracts reduced the amounts of synaptophysin in a dose-
dependent manner. Pre-treatment of neurons with COX-2-selective
inhibitors (DFU or DuP-697), but not COX-1-selective inhibitors
(valeryl salicylate or SC-560), protected neurons against the Aβ-
induced loss of synaptophysin (Fig. 2G).
PAF antagonists and CEH inhibitors reduced the Aβ-induced
translocation of COX-2 to DRMs
The above results suggested that PAF activated CEHs, and that the
consequent increased cholesterol concentrations facilitated
the translocation of COX-2 to DRMs, activation of COX-2 and
Fig. 2. Aβ caused the translocation of COX-2 into DRMs. The percentage of
(A) COX-1 or (B) COX-2 in DRMs and DSMs derived from synaptosomes
incubated with control medium (white bars), AD brain extract containing 1 nM
Aβ42 (black bars) or Aβ-depleted AD brain extract (striped bars). Values are
means±s.d. from triplicate experiments performed three times; n=9. * indicates
significantly more COX-2 in DRMs than in control synaptosomes. (C)
Immunoblots showing the amounts of caveolin, COX-1 and COX-2 in DRMs
from synaptosomes incubated with control medium or with AD brain extract
containing 1 nM Aβ42. (D) There was a significant correlation between the
amounts of COX-2 (black circles), but not COX-1 (white circles), in DRMs and
concentrations of PGE2 in synaptosomes incubated with AD brain extract
containing Aβ42 (0.125 to 1 nM); Pearson’s coefficient=0.85,P<0.01. (E) There
was a significant correlation between cholesterol concentrations and the
amounts of COX-2 in DRMs in synaptosomes incubated with AD brain extract
containing Aβ42 (0.125 to 1 nM); Pearson’s coefficient=0.85, P<0.01. (F) The
concentrations of PGE2 produced by synaptosomes pre-treated with a vehicle
control (white bars), COX-2 inhibitors (10 μM DFU or 10 μM DuP-697; black
bars) or COX-1 inhibitors [10 µM valeryl salicylate (VS) or 1 µM SC-560;
striped bars] and incubated with AD brain extract containing 1 nM Aβ42. Values
are means±s.d. from triplicate experiments performed three times; n=9. *
indicate concentrations of PGE2 significantly lower than those from control
synaptosomes incubated with AD brain extract. (G) The amounts of
synaptophysin in neurons pre-treated with a vehicle control (white bars), COX-
2 inhibitors (10 μM DFU or 10 μM DuP-697; black bars) or COX-1 inhibitors
[10 µM valeryl salicylate (VS) or 1 µMSC-560; striped bars] and incubated with
AD brain extract containing 1 nM Aβ42. Values are means±s.d. from triplicate
experiments performed three times; n=9. * indicate concentrations of
synaptophysin significantly higher than in control neurons incubated with AD
brain extract.
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the production of PGE2. In accordance with this theory, pre-
treatment of synaptosomes with PAF antagonists (H-PAF,
ginkgolide B or CV-6209) significantly reduced the Aβ-induced
translocation of COX-2 into DRMs (Fig. 3A) and PGE2 production
(Fig. 3B). Similarly, pre-treatment of synaptosomes with CEH
inhibitors [DEUP or cholesteryl N-(2-dimethylaminoethyl)-
carbamate] reduced the Aβ-induced translocation of COX-2 to
DRMs (Fig. 3C) and PGE2 production (Fig. 3D). The concentrations
of PGE2 produced by synaptosomes incubated with phospholipase
A2-activating peptide (PLAP, Bachem) were not significantly
affected by pre-treatment with PAF antagonists (1 µM H-PAF or
ginkgolide B) or CEH inhibitors [20 µM DEUP or 5 µM cholesteryl
N-(2-dimethylaminoethyl)carbamate; Fig. 3E], indicating that these
drugs did not affect cPLA2 or COX-2 directly.
COX-2 is incorporated into Aβ–PrPC complexes
We sought to determine whether COX-2 was associated with
specific DRMs. PrPC, a receptor that mediates Aβ toxicity (Laurén
et al., 2009), acts as a scaffold protein and organises signalling
complexes (Linden et al., 2012). The addition of soluble AD
brain extract to synaptosomes caused the formation of Aβ–PrPC
complexes (Fig. 4A), and there was a significant correlation
between the amounts of Aβ–PrPC complexes and the amounts of
COX-2 found within DRMs (Fig. 4B), suggesting a possible
connection. Pre-treatment of synaptosomes with COX-2 inhibitors
(DFU or DuP-697) did not affect the amounts of Aβ–PrPC
complexes formed (Fig. 4C), nor did they significantly alter the
Aβ-induced increase in synaptic cholesterol concentrations
(Fig. 4D). To isolate specific DRMs, synaptosomes incubated
with soluble AD brain extract containing 1 nM Aβ42 for 1 h were
homogenised in a non-ionic detergent and incubated with the PrPC-
reactive mAb 4F2 (a gift from Professor J. Grassi, Paris, France).
Immunoprecipitates containing PrPC and associated DRM proteins
were collected and analysed. These studies showed that CEHs did
not co-precipitate with PrPC. In contrast, cPLA2, COX-2 and the
tyrosine kinase Fyn all co-precipitated with PrPC in synaptosomes
incubated with soluble AD brain extract, but not in synaptosomes
incubated with Aβ-depleted AD brain extract (Fig. 4E). Pre-
treatment of synaptosomes with AACOCF3 or H-PAF prevented the
Aβ-induced incorporation of COX-2 and Fyn into PrPC-containing
DRMs (Fig. 4F). Similarly, pre-treatment of synaptosomes with
CEH inhibitors reduced the Aβ-induced translocation of COX-2 and
Fyn into DRMs (Fig. 4G). It is worth noting that the Aβ-induced
translocation of cPLA2 to DRMs (Bate andWilliams, 2011) was not
affected by either PAF antagonists or CEH inhibitors, nor did these
drugs affect the amounts of caveolin in DRMs (Fig. 4G).
ACAT-1 is incorporated into Aβ–PrPC complexes
The Aβ-induced changes in synaptic cholesterol concentrations are
transient, and concentrations return to basal levels after 4 h, an effect
mediated by ACAT-1 (West et al., 2017). The addition of soluble
AD brain extract to synaptosomes caused ACAT-1 to translocate
from DSMs to DRMs (Fig. 5A). The addition of Aβ-depleted AD
brain extract did not significantly alter the amounts of ACAT-1 in
DRMs. In addition, ACAT-1 co-precipitated with PrPC-containing
DRMs in synaptosomes incubated with soluble AD brain extract, but
not in synaptosomes incubated with control medium or Aβ-depleted
brain extract (Fig. 5B). Following the addition of soluble AD brain
extract containing 0.6 to 1 nM Aβ42 to synaptosomes, there were
significant correlation between cholesterol concentrations and the
amounts of ACAT-1 in DRMs (Fig. 5C), and between the amounts of
Aβ–PrPC complexes and ACAT-1 in DRMs (Fig. 5D). Pre-
treatment of synaptosomes with a cPLA2 inhibitor (AACOCF3), a
PAF antagonist (H-PAF) or a CEH inhibitor (DEUP) reduced the
Aβ-induced recruitment of ACAT-1 into DRMs (Fig. 5E,F). None
of these treatments affected the amounts of caveolin found within
DRMs (Fig. 5F).
Time-course studies showed that Aβ–PrPC complexes (Fig. 6A)
and the Aβ-induced targeting of COX-2 (Fig. 6B) and ACAT-1
(Fig. 6C) to DRMs were also transient in synaptosomes. The
return of cholesterol concentrations to those of control
synaptosomes is blocked by ACAT inhibitors (West et al.,
Fig. 3. PAF antagonists and CEH inhibitors reduced the Aβ-induced
translocation of COX-2 into DRMs. The amounts of (A) COX-2 in DRMs
and (B) PGE2 in synaptosomes pre-treated with a vehicle control or PAF
antagonists (1 µM H-PAF, ginkgolide B or CV6209) and incubated with control
medium (white bars) or AD brain extract containing 1 nM Aβ42 (black bars).
Values aremeans±s.d. from triplicate experiments performed three times; n=9.
* indicate significantly less COX-2 in DRMs or PGE2 than in control
synaptosomes incubated with AD brain extract. The amounts of (C) COX-2 in
DRMs and (D) PGE2 in synaptosomes pre-treated with a vehicle control or
CEH inhibitors [20 µM DEUP or 5 µM cholesteryl N-(2-dimethylaminoethyl)-
carbamate] and incubated with control medium (white bars) or AD brain extract
containing 1 nM Aβ42 (black bars). Values are means±s.d. from triplicate
experiments performed three times; n=9. * indicate significantly less COX-2 in
DRMs/PGE2 than in control synaptosomes incubated with AD brain extract.
(E) The concentrations of PGE2 in synaptosomes pre-treated with a vehicle
control, PAF antagonists (1 µM H-PAF or 1 µM ginkgolide B) or CEH inhibitors
[20 µM DEUP or 5 µM cholesteryl N-(2-dimethylaminoethyl)carbamate] and
incubated with control medium (white bars) or 500 nM PLAP (black bars).
Values aremeans±s.d. from triplicate experiments performed three times; n=9.
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2017). Here, we demonstrate that pre-treatment of synaptosomes
with ACAT inhibitors (TMP-153 or YIC-C8-434) significantly
increased the longevity of Aβ–PrPC complexes. Pre-treatment with
ACAT inhibitors also increased the amounts of COX-2 and ACAT-
1 in DRMs at 2 and 4 h after the addition of Aβ (Fig. 6B,C),
indicating that cholesterol esterification mediates the disruption of
signalling complexes. This hypothesis was supported by the
observation that pre-treatment with ACAT inhibitors also increased
the Aβ-induced production of PGE2 (Fig. 6D) and significantly
increases synapse damage in neurons incubated with Aβ (West
et al., 2017).
CytochalasinDblocked theAβ-induced translocation ofCOX-
2 and ACAT-1 into DRMs
Because PrPC signalling is dependent upon endocytosis (Caetano
et al., 2008), the effects cytochalasin D (100 nM), which inhibits
endocytosis into the recycling pathway (Millman et al., 2008), on
Aβ–PrPC complexes was studied. There were significantly
higher amounts of Aβ–PrPC complexes at the surface of
synaptosomes (released by the membrane-impermeable
enzyme phosphatidylinositol-phospholipase C) pre-treated with
cytochalasin D and incubated with soluble AD brain extract
containing 1 nM Aβ42 than in synaptosomes pre-treated with a
vehicle control (Fig. 7A), showing that cytochalasin D inhibited
the endocytosis of Aβ–PrPC complexes. In addition, pre-treatment
with cytochalasin D prevented the dissociation of Aβ–PrPC
complexes (Fig. 7B). In cytochalasin D-treated synaptosomes
incubated with soluble AD brain extract, both the cholesterol
concentrations (Fig. 7C) and the amount of cPLA2 within DRMs
(Fig. 7D) remained higher than those in synaptosomes pre-treated
with a vehicle control. In contrast, pre-treatment of synaptosomes
with cytochalasin D reduced the Aβ-induced translocation of
COX-2 (Fig. 7E) and ACAT-1 (Fig. 7F) into DRMs, suggesting that
these events occur within an intracellular compartment.
Co-immunoprecipitation studies with the PrPC-reactive mAb 4F2
showed that cytochalasin D reduced the Aβ-induced translocation of
COX-2 and ACAT-1 to Aβ–PrPC complexes, but did not affect the
translocation of cPLA2 or Fyn (Fig. 7G). Cytochalasin D also
reduced the Aβ-induced PGE2 production from 265±39 pM PGE2
to 91±19 pM PGE2 (n=6, P<0.01). These results suggest that Aβ
bound to PrPC forms a functional signalling complex only in an
intracellular compartment. Finally, we report that pre-treatment of
cultured neurons with 100 nM cytochalasin D reduced the
Aβ-induced loss of synaptophysin (Fig. 7H).
DISCUSSION
Although CEHs are key enzymes involved in the formation of Aβ-
induced signalling complexes (West et al., 2017), little is known
about how they are activated. Here, we show that cPLA2 and PAF
are key intermediates in the Aβ-induced activation of CEHs in
synaptosomes and that they increase cholesterol concentrations. The
increase in cholesterol concentrations facilitates the formation of
signalling complexes, leading to synapse degeneration in neurons
(Bate et al., 2010).
Fig. 4. CEH inhibitors blocked the Aβ-induced translocation of COX-2 to
DRMs. (A) The amounts of Aβ–PrPC complexes in synaptosomes incubated
with AD brain extract containing Aβ42 as shown. Values are means±s.d. from
triplicate experiments performed three times; n=9. (B) There was a significant
correlation between the amounts of Aβ–PrPC complexes and the amounts of
COX-2 in DRMs following the addition of AD brain extract containing Aβ42 (0.06
to 1 nM), Pearson’s coefficient=0.88, P<0.01. (C) The amounts of Aβ–PrPC
complexes in synaptosomes pre-treated with a vehicle control or COX-2
inhibitors (10 μMDFU or 10 μMDuP-697) and incubated with soluble AD brain
extract containing 0.5 nM Aβ42. Values are means±s.d. from triplicate
experiments performed three times; n=9. (D) The cholesterol concentrations in
synaptosomes pre-treated with a vehicle control or COX-2 inhibitors (10 μM
DFU or 10 μM DuP-697) and incubated with control medium (white bars) or
with soluble AD brain extract containing 0.5 nM Aβ42 (black bars). Values are
means±s.d. from triplicate experiments performed three times; n=9. (E) The
amounts of PrPC, CEH, cPLA2, COX-2 and Fyn in (1) synaptosomes or co-
precipitated with PrPC from synaptosomes incubated with (2) Aβ-depleted AD
brain extract or (3) AD brain extract containing 1 nM Aβ42. (F) The amounts of
PrPC, cPLA2, COX-2 and Fyn co-precipitated with PrPC from synaptosomes
pre-treated with (1) a vehicle control, (2) a cPLA2 inhibitor (1 µM AACOCF3) or
(3) a PAF antagonist (1 µM H-PAF) and incubated with AD brain extract
containing 1 nM Aβ42. (G) Immunoblot showing the amounts of caveolin,
cPLA2, COX-2 and Fyn in DRMs from synaptosomes pre-treated with (1) a
vehicle control or CEH inhibitors (2) 20 µM DEUP or (3) 5 µM cholesteryl N-(2-
dimethylaminoethyl)carbamate and incubated with AD brain extract containing
1 nM Aβ42.
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Activation of cPLA2 was a key step in the Aβ-induced increase in
synaptic cholesterol concentrations. Although activated cPLA2 can
give rise to multiple biologically active lipids, including lyso-
phospholipids, our studies were concentrated on the effects of PAF
for two reasons. Firstly, because PAF antagonists blocked the Aβ-
induced increase in synaptic cholesterol concentrations and,
secondly, because PAF also increased synaptic cholesterol
concentrations via activation of CEHs. The movement of enzymes
to and frommembranes containing substrates is a key mechanism of
cell regulation. The increase in cholesterol concentrations facilitated
the movement of key signalling enzymes, COX-2 and Fyn into
DRMs. These results support the hypothesis that Aβ activates the
COX-2 isoform. Selective COX-2 inhibitors did not affect the
formation of Aβ–PrPC complexes or the Aβ-induced increase in
synaptic cholesterol concentrations. However, COX-2-selective
inhibitors reduced the Aβ-induced increase in PGE2
concentrations and protected neurons against Aβ-induced synapse
damage. These results are consistent with reports showing that
COX-2 is expressed at the synapse (Kaufmann et al., 1996) and that
COX-2 inhibitors reverse Aβ-mediated suppression of long-term
potentiation and memory (Kotilinek et al., 2008).
In synaptosomes incubated with Aβ, COX-2 co-precipitated with
PrPC, cPLA2 and Fyn, suggesting that it formed part of a signalling
complex. The Aβ-induced translocation of COX-2 and Fyn to Aβ–
PrPC complexes and the production of PGE2 were dependent upon
the PAF-induced increase in cholesterol concentrations. PAF
antagonists and CEH inhibitors did not affect all DRM proteins;
for example, they did not affect the amounts of caveolin in DRMs,
nor did they affect the Aβ-induced translocation of cPLA2 to DRMs.
Fig. 6. Cholesterol esterification dispersed Aβ–PrPC complexes. (A) The
amounts of Aβ–PrPC complexes in synaptosomes pre-treated with a vehicle
control (white bars) or ACAT inhibitors (TMP-153, black bars or YIC-C8-434,
striped bars) and incubated with AD brain extract containing 1 nM Aβ42 for
time periods as shown. Values are means±s.d. from triplicate experiments
performed three times; n=9. * indicate amounts of Aβ–PrPC complexes
significantly higher than in untreated synaptosomes incubated with AD
brain extract. The amounts of (B) COX-2 and (C) ACAT-1 within DRMs in
synaptosomes pre-treatedwith a vehicle control (white bars) or ACAT inhibitors
(TMP-153, black bars or YIC-C8-434, striped bars) and incubated with
AD brain extract containing 1 nM Aβ42 for time periods as shown. Values are
means±s.d. from triplicate experiments performed three times; n=9.
* indicate amounts of COX-2 or ACAT-1 significantly higher than in control
synaptosomes incubated with AD brain extract. (D) The concentrations of
PGE2 produced by synaptosomes pre-treated with a vehicle control, 100 nM
TMP-153 or 100 nM YIC-C8-434 and incubated with control medium (white
bars) or with AD brain extract containing 1 nM Aβ42 (black bars). * indicate
concentrations of PGE2 significantly higher than control synaptosomes
incubated with AD brain extract.
Fig. 5. Aβ caused the translocation of ACAT-1 to PrPC complexes. (A) The
amounts of ACAT-1 in DRMs and DSMs from synaptosomes incubated with
control medium (white bars), AD brain extract containing 1 nM Aβ42 (black
bars) or Aβ-depleted AD brain extract (striped bars). Values are means±s.d.
from triplicate experiments performed three times; n=9. * indicates significantly
more ACAT-1 than in control synaptosomes. (B) Immunoblots showing the
amounts of ACAT-1 co-precipitated with PrPC from synaptosomes incubated
with (1) control medium, (2) Aβ-depleted AD brain extract or (3) AD brain extract
containing 1 nM Aβ42. There were significant correlations between (C) the
amounts of ACAT-1 in DRMs and cholesterol concentrations; Pearson’s
coefficient=0.82, P<0.01, and (D) the amounts of ACAT-1 in DRMs and Aβ–
PrPC complexes; Pearson’s coefficient=0.94, P<0.01, following the addition of
AD brain extract containing Aβ42 (0.06 to 1 nM) to synaptosomes. (E) The
amounts of ACAT-1 in DRMs from synaptosomes pre-treated with a vehicle
control, 1 μM AACOCF3, 1 μM H-PAF or 20 μM DEUP and incubated with
control medium (white bars) or AD brain extract containing 1 nM Aβ42 (black
bars). * indicate significantly less ACAT-1 than in control synaptosomes
incubated with AD brain extract. (F) Immunoblots showing the amounts of
caveolin and ACAT-1 in DRMs from synaptosomes pre-treated with (1) a
vehicle control, (2) 1 μM AACOCF3, (3) 1 μM H-PAF or (4) 20 μM DEUP and
incubated with AD brain extract containing 1 nM Aβ42.
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Furthermore, neither PAF antagonists nor CEH inhibitors affected
the production of PGE2 by synaptosomes incubated with PLAP,
indicating that they do not affect cPLA2 or COX-2 directly. These
observations are consistent with the hypothesis that PAF antagonists
and CEH inhibitors modify the membrane environment generated
by Aβ that leads to PGE2 production.
Aβ is produced as part of normal neuronal metabolism (Haass
et al., 1992), and plays a role in regular synapse function and
memory formation (Abramov et al., 2009; Garcia-Osta and
Alberini, 2009; Puzzo et al., 2011). The observations that PAF
and PGE2 affect synapse function and memory formation at
physiological concentrations (Chen and Bazan, 2005; Chen et al.,
2001; Clark et al., 1992; Kato et al., 1994; Koch et al., 2010) are
consistent with the theory that Aβ-induced activation of cPLA2 and
the production of PAF and PGE2 are part of normal synapse
function. The observations that concentrations of PAF (Ryan et al.,
2009) and PGE2 (Montine et al., 1999) are elevated in the brains of
AD patients indicate that this pathway is activated in the brains of
AD patients. Reports showing that PAF and PGE2 cause synapse
damage in cultured neurons (Bate et al., 2010) suggest that aberrant
activation of this pathway causes synapse degeneration.
Consequently, it is crucial to understand how this pathway is
controlled.
The Aβ-induced translocation of ACAT-1 into DRMs, and more
specifically Aβ–PrPC complexes, was dependent upon PAF and
CEH. Aβ–PrPC complexes in synaptosomes were transient, and
there was a close temporal association between cholesterol
concentrations and Aβ–PrPC complexes (West et al., 2017).
Notably, pre-treatment of neurons with ACAT inhibitors
significantly enhanced Aβ-induced synapse damage (West et al.,
2017). Here, we show that pharmacological inhibition of ACAT
reduced the dissociation of Aβ–PrPC complexes, increasing the
time COX-2 and ACAT-1 were found in DRMs and significantly
increased the Aβ-induced production of PGE2. ACAT inhibitors
have been proposed as AD treatments as they reduce the
production of Aβ, and ablation of ACAT-1 reduces pathology in
transgenic AD mice (Bryleva et al., 2010; Puglielli et al., 2001).
However, in these studies, ACAT was inhibited, or ablated, before
pathology developed. Consequently, ACAT inhibitors might be
able to prevent the development of AD pathology but may be
contraindicated in the latter stages of AD, where concentrations of
Aβ are already raised.
Although inhibition of endocytosis by means of cytochalasin D
significantly reduced the Aβ-induced production of PGE2, it had
diverse effects upon the Aβ-induced signalling complex.
Cytochalasin D disrupted the relationships between Aβ–PrPC
complexes, cholesterol concentrations and enzymes involved in
PGE2 production. Firstly, cytochalasin D maintained the Aβ-
induced increase in cholesterol concentrations, stabilised Aβ–PrPC
complexes and increased the time cPLA2 spent in DRMs. Although
these changes might be expected to increase PGE2 production,
cytochalasinD also prevented theAβ-induced translocation ofCOX-2
to DRMs/Aβ–PrPC complexes. In addition, cytochalasin D reduced
the Aβ-induced translocation of ACAT-1 to DRMs and Aβ–PrPC
complexes. The lack of ACAT-1 in DRMs explains the maintenance
of high cholesterol concentrations and, consequently, the longevity of
complexes in synaptosomes.
Collectively, these results suggest that Aβ causes a tri-phasic
response. Firstly, aggregation of cell surface PrPC by Aβ oligomers
led to the translocation of cPLA2 into DRMs, the activation of
cPLA2 and the release of PAF (Fig. 8A). PAF activated CEHs,
resulting in the increased cholesterol concentrations that stabilised
Fig. 7. Cytochalasin D blocked the Aβ-induced translocation of COX-2
and ACAT-1 into signalling complexes. (A) The amounts of Aβ–PrPC
complexes at the surface of synaptosomes, and (B) total amounts of Aβ–PrPC
complexes in synaptosomes after pre-treatment with a vehicle control (black
circles) or 100 nM cytochalasin D (white squares) and incubation with AD
brain extract containing 1 nM Aβ42. Values are means±s.d. from triplicate
experiments performed three times; n=9. (C) The concentrations of cholesterol
and the amounts of (D) cPLA2, (E) COX-2 and (F) ACAT-1 in DRMs from
synaptosomes pre-treated with a vehicle control (black circles) or 100 nM
cytochalasin D (white squares) and incubated with AD brain extract containing
1 nM Aβ42. Values are means±s.d. from triplicate experiments performed three
times; n=9. (G) The amounts of PrPC, cPLA2, Fyn, COX-2 and ACAT-1 in
DRMs precipitated by the anti-PrPC mAb 4F2 in synaptosomes pre-treated
with a vehicle control or 100 nM cytochalasin D and incubated with AD brain
extract containing 1 nM Aβ42. (H) The amounts of synaptophysin in neuronal
cultures pre-treated with a vehicle control (black circles) or 100 nM
cytochalasin D (white squares) and incubated with AD brain extract containing
Aβ42 as shown. Values are means±s.d. from triplicate experiments performed
three times; n=9.
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Aβ–PrPC–cPLA2 complexes and recruited Fyn (Fig. 8B). Secondly,
endocytosis of Aβ–PrPC–cPLA2–Fyn complexes allowed the
recruitment of COX-2 into the complex, leading to PGE2
production (Fig. 8C). The third phase occurred when ACAT-1
was recruited into Aβ–PrPC–cPLA2–COX-2–Fyn complexes
(Fig. 8D). The subsequent esterification of cholesterol reduced
cholesterol concentrations, and led to the dispersal of complexes
and the loss of cPLA2, COX-2 and ACAT-1 from DRMs. These
observations indicate that cholesterol esterification led to the
dissociation of signalling complexes and reduced cell signalling.
In summary, the key finding of this study is that the Aβ-induced
activation of CEH and increase in cholesterol concentrations in
synaptosomes was dependent upon activated cPLA2 and PAF. The
increased cholesterol concentrations were associated with the
migration of COX-2 and Fyn into lipid rafts and the production of
PGE2, a bioactive lipid that causes synapse degeneration at high
concentrations. Crucially, this signalling pathway also facilitated the
migration of ACAT-1 into the Aβ–PrPC–cPLA2–COX-2–Fyn
complex. The subsequent cholesterol esterification reduced free
cholesterol concentrations, resulting in the dissociation of this
complex and the cessation of cell signalling.
MATERIALS AND METHODS
Primary neuronal cultures
Primary cortical neurons were prepared from the brains of mouse embryos
(day 15.5) after mechanical dissociation. A total of 5×105 cells/well were
dispensed in 48-well plates in Ham’s F12 containing 5% fetal calf serum for
2 h. Cultures were shaken (600 rpm for 5 min), and non-adherent cells
removed by two washes in phosphate-buffered saline (PBS). Neurons were
grown in neurobasal medium containing B27 components and nerve growth
factor (5 ng/ml) (Sigma-Aldrich) for 10 days. Immunostaining showed that,
after 10 days culture, less than 5% of the viable cells stained for glial
fibrillary acidic protein (GFAP) or F4/80 (astrocytes or microglial cells).
Neurons were pre-treated with test compounds or vehicle controls for 1 h
before the addition of test samples, including Aβ preparations or PLAP
(Bachem), for 24 h. Stock solutions of these drugs were prepared in ethanol
or dimethyl sulphoxide; vehicle controls consisted of equivalent dilutions
of ethanol or dimethyl sulphoxide in neurobasal medium and B27
components. The culture medium was used as control medium
(neurobasal medium containing B27 components). All experiments were
performed in accordance with European regulations (European community
Council Directive, 1986, 56/609/EEC) and were approved by the Royal
Veterinary College ethical committee.
Isolation of synaptosomes
Synaptosomes were prepared on a discontinuous Percoll gradient, based on
methods previously described (Thais et al., 2006). Briefly, 106 neurons were
homogenised at 4°C in 1 ml of SED solution (0.32 M sucrose, 50 mM Tris-
HCl pH 7.4, 1 mMEDTA and 1 mM dithiothreitol) and centrifuged (1000 g
for 5 min). The supernatant was transferred to a four-step gradient of 3%,
10%, 15% and 23% Percoll in SED solution and centrifuged at 16,000 g for
30 min at 4°C. The synaptosomes were collected from the interface of the
15% and 23% Percoll steps and washed in PBS at 4°C. Freshly prepared
synaptosomes were pre-treated with test compounds for 30 min and
incubated with peptides for 1 h or the time stated. At the end of the
experiment, synaptosomes were centrifuged at 16,000 g for 5 min at 4°C,
and either total membrane extracts or DRMs were isolated as below.
To access the amounts ofAβ–PrPC complexes at the surface of synaptosomes,
synaptosomes were incubated with 0.5 ml phosphatidylinositol-specific
phospholipase C (from Bacillus cereus, Sigma-Aldrich) for 10 min. This
enzyme is cell impermeable and, consequently, only released PrPC expressed on
the surface of synaptosomes. Treated synaptosomes were centrifuged (16,000 g
for 5 min), and the supernatant was collected and tested for Aβ–PrPC complexes
(see below).
Fig. 8. Putative control of synaptic
signalosome created by Aβ oligomers. (A) The
binding of Aβ oligomers links PrPC within lipid
rafts; this recruits and activates cPLA2 leading to
the production of PAF. (B) PAF activates CEHs,
causing the release of cholesterol into the
membrane. The increase in cholesterol stabilises
signalling complexes and recruits the tyrosine
kinase Fyn. (C) Following endocytosis, COX-2 is
recruited into the complex, leading to the release
of PGE2. High concentrations of PGE2 cause
synapse degeneration. (D) Recruitment of ACAT-
1 into the complex results in the esterification of
cholesterol, reduced cholesterol concentrations
and the dispersal of lipid raft signalling complexes.
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Total neuron and synaptosome extracts
Treated cells or synaptosomes were washed twice in PBS and homogenised
in an extraction buffer containing 10 mM Tris-HCl, 100 mM NaCl, 10 mM
EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate and 0.2% SDS at
106 cells/ml. Mixed protease inhibitors [4-(2-aminoethyl)benzenesulfonyl
fluoride hydrochloride, aprotinin, leupeptin, bestatin, pepstatin A and E-46;
Sigma-Aldrich] were added, and large insoluble fragments were removed by
centrifugation (1000 g for 5 min).
Isolation of DRMs
DRMs were isolated by using their insolubility in non-ionic detergents, as
described (London and Brown, 2000). Briefly, synaptosomes were
homogenised in an ice-cold buffer containing 1% Triton X-100, 10 mM
Tris-HCl, pH 7.2, 150 mM NaCl, 10 mM EDTA and mixed protease
inhibitors (as above), and large fragments were removed by centrifugation
(1000 g for 5 min at 4°C). The supernatant was incubated on ice (4°C) for
1 h and centrifuged (16,000 g for 30 min at 4°C). The supernatant (DSM)
was collected. The insoluble pellet was homogenised in an extraction buffer
containing 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM EDTA, 0.5%
Nonidet P-40, 0.5% sodium deoxycholate, 0.2% SDS and mixed protease
inhibitors, and centrifuged (10 min at 16,000 g). The soluble material was
reserved as the DRM fraction.
Co-precipitation studies
Synaptosomes were homogenised in an ice-cold buffer containing 1%
Triton X-100 (as above), and large fragments were removed by
centrifugation (1000 g for 5 min at 4°C). The supernatant was incubated
with 1 µg/ml of the PrPC-reactive mAb 4F2 or an isotype control for 1 h at
4°C, followed by the addition of 10 µl of protein G-coated beads (Sigma-
Aldrich) for a further 10 min. The mixture was centrifuged at 1000 g for
5 min to collect beads and the attached PrPC-containing DRMs. Beads were
washed twice in ice-cold 1% Triton X-100 before use.
Western blotting
Samples were mixed with Laemmli buffer containing β-mercaptoethanol
and heated to 95°C for 5 min; proteins were separated by electrophoresis on
15% polyacrylamide gels. Proteins were transferred onto a Hybond-P
polyvinylidene membrane by semi-dry blotting and membranes blocked
using 10% milk powder. Antibodies used are listed in Table S1. These
were visualised using a combination of biotinylated anti-mouse/goat/
rat/rabbit IgG (Sigma-Aldrich), extravidin–peroxidase and enhanced
chemiluminescence.
Brain extracts
Soluble extracts from brain tissue (temporal lobes supplied by Asterand;
informed consent was given to Asterand, and samples were collected
according to the Declaration of Helsinki, 2000) of three patients with a
clinical and pathologically-confirmed diagnosis of Alzheimer’s disease
were prepared, using methods as previously described (Shankar et al.,
2008). Briefly, brain tissue was cut into approximately 100 mg pieces and
added to 2 ml tubes containing lysing matrix D beads (Q-Bio). Tris-buffered
saline (20 mM Tris-HCl, pH 7.4, 150 mM NaCl,) was added, so that there
was the equivalent of 100 mg brain tissue/ml. Tubes were shaken for 10 min
(Disruptor Genie, Scientific Industries) and centrifuged at 16,000 g for
10 min to remove cell debris. Soluble material was passed through a 50 kDa
filter (Sartorius) to remove any protease activity, and desalted (3 kDa filter;
Sartorius) to remove drugs and small molecules. The retained material
contained peptides from 3-50 kDa and were stored at −80°C. For biological
experiments, the soluble AD brain extracts were diluted in neurobasal
medium containing B27 components. For immunoblot analysis, extracts
were mixed with an equal volume of 0.5% NP-40, 5 mM CHAPS, 50 mM
Tris-HCl, pH 7.4 and separated by polyacrylamide gel electrophoresis.
Proteins were transferred onto a polyvinylidene membrane by semi-dry
blotting and blocked using 10% milk powder. Aβ was detected by
incubation with mAb 6E10 (reactive with an epitope 1-16 of Aβ; Covance,
SIG 39340), biotinylated anti-mouse IgG, extravidin–peroxidase and
enhanced chemiluminescence.
Immunodepletions
Soluble AD brain extracts were incubated with 1 μg/ml mAb 4G8 (reactive
with epitope 17-24 of Aβ; Covance, SIG-39220) or 1 μg/ml mAb LN27
[reactive with epitope 45 to 53 of the amyloid precursor protein; Covance,
SIG-39188 (mock-depletion)] and incubated at 4°C on rollers for 1 h.
Protein G microbeads (Sigma-Aldrich) were added (10 µl/ml) for 30 min
and protein G bound-antibody complexes removed by centrifugation at
16,000 g for 5 min. The treated AD brain extracts were filtered (0.2 µM;
Sartorius) before use.
Synaptophysin ELISA
The amount of synaptophysin in neuronal extracts wasmeasured by enzyme-
linked immunosorbent assay (ELISA), as previously described (Bate et al.,
2010). Maxisorb immunoplates (Nunc) were coated with 1 µg/ml of a mouse
anti-synaptophysin mAb (MAB368; Millipore) as a capture antibody.
Samples were applied (1 h at room temperature), and bound synaptophysin
was detected using 1 µg/ml rabbit polyclonal anti-synaptophysin (Abcam,
ab53166), followed by an anti-rabbit IgG conjugated to alkaline phosphatase
(Sigma-Aldrich, A3687) and 1 mg/ml 4-nitrophenol phosphate solution
(Sigma-Aldrich). Absorbance was measured on a microplate reader at
405 nm. Samples were expressed as ‘units synaptophysin’, where 100 units
was defined as the amount of synaptophysin in 106 untreated neurons.
cPLA2 ELISA and PGE2 measurement
The amounts of cPLA2 in extracts was measured by ELISA, as previously
described (West et al., 2017). Maxisorb immunoplates were coated with
0.5 µg/ml of mouse mAb anti-cPLA2 (clone CH-7; Upstate, 05-568) and
blocked with 5% milk powder in PBS+0.1% Tween-20 (PBST). Samples
were added for 1 h and the amount of bound cPLA2 was detected using a
goat polyclonal anti-cPLA2 (Santa-Cruz Biotechnology, sc-4049),
followed by biotinylated anti-goat IgG, extravidin–alkaline phosphatase
and 1 mg/ml 4-nitrophenol phosphate solution. Absorbance was measured
at 405 nm and the amount of cPLA2 protein expressed in units; 100 units
was defined as the amount of cPLA2 in control preparations.
The concentrations of PGE2 and PAF in synaptosomes were determined
using competitive enzyme immunoassay kits (R&D Systems, Abingdon,
UK), according to the manufacturer’s instructions.
COX-1 ELISA
Maxisorb immunoplates were coated with 1 µg/ml mouse mAb to amino
acids 575 to 602 of COX-1 (H-1, sc-166572, Santa Cruz Biotechnology)
overnight and blocked with 5% milk powder. Samples were added for 1 h,
and the amount of bound COX-1 was detected with 0.5 μg/ml of a rabbit
polyclonal IgG to amino acids 63 to 124 of COX-1 (H-62, sc-7950, Santa
Cruz Biotechnology), followed by a biotinylated anti-rabbit IgG (1:2000),
extravidin–alkaline phosphatase and 1 mg/ml 4-nitrophenol phosphate
solution. Absorbance was measured at 405 nm, and results were
expressed as the percentage of COX-1, where 100% was defined as the
amount of COX-1 in control synaptosomes.
COX-2 ELISA
Maxisorb immunoplates were coated with 1 µg/ml mouse mAb (5E10/
D10; Enzo Life Sciences) overnight and blocked with 5% milk powder.
Samples were added for 1 h, and the amount of bound COX-2 was
detected with 0.5 μg/ml of rabbit polyclonal IgG to epitope 50 to 111
(H-62; Santa Cruz, sc-7951), followed by a biotinylated rabbit anti-goat
IgG (Sigma, 1:2000), extravidin–alkaline phosphatase and 1 mg/ml 4-
nitrophenol phosphate solution. Absorbance was measured at 405 nm,
and results were expressed as the percentage of COX-2, where 100%
was defined as the amount of COX-2 in control synaptosomes.
ACAT-1 ELISA
Maxisorb immunoplates were coated with 1 µg/ml rabbit monoclonal anti-
ACAT-1 (EPR10359; ab168342, Abcam, 1:1000) overnight and blocked
with 5% milk powder in PBS+2% Tween-20. Samples were added for 1 h,
and the amount of bound ACAT-1 was detected with 0.5 μg/ml of a goat
polyclonal IgG (G-15; sc-161307, Santa Cruz Biotechnology), followed
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by a biotinylated rabbit anti-goat IgG (1:2000), extravidin–alkaline
phosphatase and 1 mg/ml 4-nitrophenol phosphate solution. Absorbance
was measured at 405 nm, and results were expressed as the percentage of
ACAT-1, where 100% was defined as the amount of ACAT-1 in control
synaptosomes.
Aβ–PrPC complex ELISA
The amounts of Aβ–PrPC complexes in synaptosomes was measured by
ELISA, as previously described (West et al., 2017). Maxisorb immunoplates
were coated with mAb 4F2 reactive with PrPC. Plates were blocked with 5%
milk powder, and samples were added for 1 h. Aβ bound to PrPC was
detected by using biotinylated mAb 6E10 (Covance). Bound Aβ was
detected using extravidin–alkaline phosphatase and 1 mg/ml 4-nitrophenol
phosphate solution, and absorbance was measured at 405 nm. Samples were
expressed as a percentage of maximum optical density in control
synaptosomes.
Preparation of samples for Aβ42 ELISA
To detach Aβ42 from membrane components that blocked specific epitopes,
samples (300 µl) were mixed with 700 µl of propan-2-ol and sonicated.
Proteins were precipitated by addition of 250 µl 100% w/v trichloroacetic
acid, incubation on ice for 30 min and centrifugation (16,000 g for 10 min at
4°C). The pellet was washed twice with ice-cold acetone, dried, suspended
in a buffer containing 150 mM NaCl, 10 mM Tris-HCl, pH 7.4, 10 mM
EDTA and 0.2% SDS, and sonicated.
Aβ42 ELISA
Nunc Maxisorb immunoplates were coated with mAb 4G8 in carbonate
buffer overnight. Plates were blocked with 5% milk powder in PBST, and
samples were applied. The detection antibody was an Aβ42-selective rabbit
mAb BA3-9 (Covance, SIG-39168), followed by biotinylated anti-rabbit
IgG and extravidin–alkaline phosphatase. Total Aβ was visualised by
addition of 1 mg/ml p-nitrophenol phosphate solution, and optical density at
405 nm was measured in a spectrophotometer.
Cholesterol content
The concentrations of cholesterol in samples were measured using the
Amplex Red cholesterol assay kit (Life Technologies, Paisley, UK) (Robinet
et al., 2010), according to the manufacturer’s instructions. Briefly,
cholesterol was oxidised by cholesterol oxidase to yield hydrogen
peroxide and ketones. The hydrogen peroxide reacted with 10-acetyl-3,7-
dihydroxyphenoxazine (Amplex Red reagent) to produce highly fluorescent
resorufin, which was measured by excitation at 550 nm and emission
detection at 590 nm. By performing the assay in the presence or absence of
cholesterol esterase, wewere also able to determine the amounts of esterified
cholesterol within samples. Each experiment contained cholesterol
standards and solvent-only controls. Cholesterol concentrations were
calculated by reference to the cholesterol standards.
Statistical methods
Differences between treatment groups were assessed using paired Student’s
t-tests, and one-way and two-way ANOVAwith Bonferroni’s post hoc tests
(IBM SPSS statistics 20). Error values are ±s.d. Correlations were
determined using bivariate analysis, and significance was set at 0.01%.
Acknowledgements
We would like to thank Professor Alun Williams (Cambridge University, UK) for
supplying human brain material.
Competing interests
The authors declare no competing or financial interests.
Author contributions
Conceptualization: C.O., E.W., C.B.; Methodology: C.O., E.W., C.B.; Formal
analysis: C.B.; Investigation: C.O., E.W., C.B.; Data curation: C.O., E.W., C.B.;
Writing - original draft: C.B.; Writing - review & editing: C.B.; Supervision: C.B.;
Project administration: C.B.
Funding
This work was funded by the Royal Veterinary College Bioveterinary Sciences
undergraduate project funds.
Supplementary information
Supplementary information available online at
http://jcs.biologists.org/lookup/doi/10.1242/jcs.211789.supplemental
References
Abramov, E., Dolev, I., Fogel, H., Ciccotosto, G. D., Ruff, E. and Slutsky, I.
(2009). Amyloid-[beta] as a positive endogenous regulator of release probability at
hippocampal synapses. Nat. Neurosci. 12, 1567-1576.
Bate, C. and Williams, A. (2011). Amyloid-β-induced synapse damage is mediated
via cross-linkage of the cellular prion protein. J. Biol. Chem. 286, 37955-37963.
Bate, C., Tayebi, M. and Williams, A. (2010). Phospholipase A2 inhibitors protect
against prion and Aβmediated synapse degeneration.Mol. Neurodegener. 5, 13.
Bhattacharyya, D. K., Lecomte, M., Dunn, J., Morgans, D. J. and Smith, W. L.
(1995). Selective inhibition of prostaglandin endoperoxide synthase-1
(Cyclooxygenase-1) by valerylsalicylic acid. Arch. Biochem. Biophys. 317, 19-24.
Brown, D. A. and London, E. (2000). Structure and function of sphingolipid- and
cholesterol-rich membrane rafts. J. Biol. Chem. 275, 17221-17224.
Bryleva, E. Y., Rogers, M. A., Chang, C. C. Y., Buen, F., Harris, B. T., Rousselet,
E., Seidah, N. G., Oddo, S., LaFerla, F. M., Spencer, T. A. et al. (2010). ACAT1
gene ablation increases 24(S)-hydroxycholesterol content in the brain and
ameliorates amyloid pathology in mice with AD. Proc. Natl. Acad. Sci. USA 107,
3081-3086.
Caetano, F. A., Lopes, M. H., Hajj, G. N. M., Machado, C. F., Pinto Arantes, C.,
Magalhaes, A. C., Vieira, M. D. P. B., Americo, T. A., Massensini, A. R., Priola,
S. A. et al. (2008). Endocytosis of prion protein is required for ERK1/2 signaling
induced by stress-inducible protein 1. J. Neurosci. 28, 6691-6702.
Chang, T.-Y., Chang, C. C. Y., Ohgami, N. and Yamauchi, Y. (2006). Cholesterol
sensing, trafficking, and esterification. Annu. Rev. Cell Dev. Biol. 22, 129-157.
Chen, C. and Bazan, N. G. (2005). Endogenous PGE2 regulates membrane
excitability and synaptic transmission in hippocampal CA1 pyramidal neurons.
J. Neurphysiol. 93, 929-941.
Chen, C., Magee, J. C., Marcheselli, V., Hardy, M. and Bazan, N. G. (2001).
Attenuated LTP in hippocampal dentate gyrus neurons of mice deficient in the
PAF receptor. J. Neurophysiol. 85, 384-390.
Chiesa, R., Piccardo, P., Biasini, E., Ghetti, B. and Harris, D. A. (2008).
Aggregated, wild-type prion protein causes neurological dysfunction and synaptic
abnormalities. J. Neurosci. 28, 13258-13267.
Clark, G. D., Happel, L. T., Zorumski, C. F. andBazan, N. G. (1992). Enhancement
of hippocampal excitatory synaptic transmission by platelet-activating factor.
Neuron 9, 1211-1216.
Copeland, R. A., Williams, J. M., Giannaras, J., Nurnberg, S., Covington, M.,
Pinto, D., Pick, S. and Trzaskos, J. M. (1994). Mechanism of selective inhibition
of the inducible isoform of prostaglandin G/H synthase. Proc. Natl. Acad. Sci. USA
91, 11202-11206.
Garcia-Osta, A. and Alberini, C. M. (2009). Amyloid beta mediates memory
formation. Learn. Mem. 16, 267-272.
Gylys, K. H., Fein, J. A., Yang, F., Miller, C. A. and Cole, G. M. (2007). Increased
cholesterol in A[beta]-positive nerve terminals from Alzheimer’s disease cortex.
Neurobiol. Aging 28, 8-17.
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A.,
Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D. and Teplow, D. B.
(1992). Amyloid β-peptide is produced by cultured cells during normal
metabolism. Nature 359, 322-325.
Herms, J., Tings, T., Gall, S., Madlung, A., Giese, A., Siebert, H., Schurmann, P.,
Windl, O., Brose, N. and Kretzschmar, H. (1999). Evidence of presynaptic
location and function of the prion protein. J. Neurosci. 19, 8866-8875.
Kato, K., Clark, G. D., Bazan, N. G. and Zorumski, C. F. (1994). Platelet-activating
factor as a potential retrograde messenger in CA1 hippocampal long-term
potentiation. Nature 367, 175-179.
Kaufmann, W. E., Worley, P. F., Pegg, J., Bremer, M. and Isakson, P. (1996).
COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at
postsynaptic sites in rat cerebral cortex. Proc. Natl. Acad. Sci. USA 93,
2317-2321.
Koch, H., Huh, S.-E., Elsen, F. P., Carroll, M. S., Hodge, R. D., Bedogni, F.,
Turner, M. S., Hevner, R. F. and Ramirez, J.-M. (2010). Prostaglandin E2-
induced synaptic plasticity in neocortical networks of organotypic slice cultures.
J. Neurosci. 30, 11678-11687.
Kotilinek, L. A., Westerman, M. A., Wang, Q., Panizzon, K., Lim, G. P., Simonyi,
A., Lesne, S., Falinska, A., Younkin, L. H., Younkin, S. G. et al. (2008).
Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of
memory and synaptic plasticity. Brain 131, 651-664.
Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L.,
Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E. et al. (2004). Synaptic
targeting by Alzheimer’s-related amyloid β oligomers. J. Neurosci. 24,
10191-10200.
10
RESEARCH ARTICLE Journal of Cell Science (2018) 131, jcs211789. doi:10.1242/jcs.211789
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W. and Strittmatter, S. M.
(2009). Cellular prion protein mediates impairment of synaptic plasticity by
amyloid-β oligomers. Nature 457, 1128-1132.
Linden, R., Cordeiro, Y. and Lima, L. M. T. R. (2012). Allosteric function and
dysfunction of the prion protein. Cell. Mol. Life Sci. 69, 1105-1124.
London, E. and Brown, D. A. (2000). Insolubility of lipids in Triton X-100: physical
origin and relationship to sphingolipid/cholesterol membrane domains (rafts).
Biochim. Biophys. Acta 1508, 182-195.
Millman, E. E., Zhang, H., Godines, V., Bean, A. J., Knoll, B. J. and Moore, R. H.
(2008). Rapid recycling of beta-adrenergic receptors is dependent on the actin
cytoskeleton and myosin Vb. Traffic 9, 1958-1971.
Montine, T. J., Sidell, K. R., Crews, B. C., Markesbery, W. R., Marnett, L. J.,
Roberts, L. J. andMorrow, J. D. (1999). Elevated CSF prostaglandin E2 levels in
patients with probable AD. Neurology 53, 1495-1498.
Mouillet-Richard, S., Ermonval, M., Chebassier, C., Laplanche, J. L., Lehmann,
S., Launay, J. M. and Kellermann, O. (2000). Signal transduction through prion
protein. Science 289, 1925-1928.
Palavicini, J. P., Wang, C., Chen, L., Hosang, K., Wang, J., Tomiyama, T., Mori,
H. and Han, X. (2017). Oligomeric amyloid-beta induces MAPK-mediated
activation of brain cytosolic and calcium-independent phospholipase A2 in a
spatial-specific manner. Acta Neuropathol. Commun. 5, 56.
Puglielli, L., Konopka, G., Pack-Chung, E., Ingano, L. A. M. K., Berezovska, O.,
Hyman, B. T., Chang, T. Y., Tanzi, R. E. and Kovacs, D. M. (2001). Acyl-
coenzyme A: cholesterol acyltransferasemodulates the generation of the amyloid
beta-peptide. Nat. Cell Biol. 3, 905-912.
Puzzo, D., Privitera, L., Fa, M., Staniszewski, A., Hashimoto, G., Aziz, F.,
Sakurai, M., Ribe, E. M., Troy, C. M., Mercken, M. et al. (2011). Endogenous
amyloid-β is necessary for hippocampal synaptic plasticity and memory. Ann.
Neurol. 69, 819-830.
Rajendran, L. and Simons, K. (2005). Lipid rafts and membrane dynamics. J. Cell
Sci. 118, 1099-1102.
Riendeau, D., Percival, M. D., Boyce, S., Brideau, C., Charleson, S., Cromlish,
W., Ethier, D., Evans, J., Falgueyret, J.-P., Ford-Hutchinson, A. W. et al.
(1997). Biochemical and pharmacological profile of a tetrasubstituted furanone as
a highly selective COX-2 inhibitor. Br. J. Pharmacol. 121, 105-117.
Robinet, P., Wang, Z., Hazen, S. L. and Smith, J. D. (2010). A simple and sensitive
enzymatic method for cholesterol quantification in macrophages and foam cells.
J. Lipid Res. 51, 3364-3369.
Ryan, S. D., Whitehead, S. N., Swayne, L. A., Moffat, T. C., Hou, W., Ethier, M.,
Bourgeois, A. J. G., Rashidian, J., Blanchard, A. P., Fraser, P. E. et al. (2009).
Amyloid-β42 signals tau hyperphosphorylation and compromises neuronal
viability by disrupting alkylacylglycerophosphocholine metabolism. Proc. Natl.
Acad. Sci. USA 106, 20936-20941.
Sang, N., Zhang, J., Marcheselli, V., Bazan, N. G. and Chen, C. (2005).
Postsynaptically synthesized prostaglandin E2 (PGE2) modulates hippocampal
synaptic transmission via a presynaptic PGE2 EP2 receptor. J. Neurosci. 25,
9858-9870.
Selkoe, D. J. (2002). Alzheimer’s disease is a synaptic failure. Science 298,
789-791.
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith,
I., Brett, F. M., Farrell, M. A., Rowan,M. J., Lemere, C. A. et al. (2008). Amyloid-β
protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity
and memory. Nat. Med. 14, 837-842.
Smith, C. J., Zhang, Y., Koboldt, C. M., Muhammad, J., Zweifel, B. S., Shaffer,
A., Talley, J. J., Masferrer, J. L., Seibert, K. and Isakson, P. C. (1998).
Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl Acad.
Sci. USA 95, 13313-13318.
Solforosi, L., Criado, J. R., McGavern, D. B., Wirz, S., Sanchez-Alavez, M.,
Sugama, S., DeGiorgio, L. A., Volpe, B. T., Wiseman, E., Abalos, G. et al.
(2004). Cross-linking cellular prion protein triggers neuronal apoptosis in vivo.
Science 303, 1514-1516.
Takahashi, R. H., Capetillo-Zarate, E., Lin, M. T., Milner, T. A. and Gouras, G. K.
(2010). Co-occurrence of Alzheimer’s disease beta-amyloid and tau pathologies
at synapses. Neurobiol. Aging 31, 1145-1152.
Taraboulos, A., Scott, M., Semenov, A., Avrahami, D., Laszlo, L., Prusiner, S. B.
and Avraham, D. (1995). Cholesterol depletion and modification of COOH-
terminal targeting sequence of the prion protein inhibit formation of the scrapie
isoform. J. Cell Biol. 129, 121-132.
Thais, M. E., Carqueja, C. L., Santos, T. G., Silva, R. V., Stroeh, E., Machado,
R. S., Wahlheim, D. O., Bianchin, M. M., Sakamoto, A. C., Brentani, R. R. et al.
(2006). Synaptosomal glutamate release and uptake in mice lacking the cellular
prion protein. Brain Res. 1075, 13-19.
West, E., Osborne, C. and Bate, C. (2017). The cholesterol ester cycle regulates
signalling complexes and synapse damage caused by amyloid-β. J. Cell Sci. 130,
3050-3059.
Xu, X., Bittman, R., Duportail, G., Heissler, D., Vilcheze, C. and London, E.
(2001). Effect of the structure of natural sterols and sphingolipids on the formation
of ordered sphingolipid/sterol domains (rafts). Comparison of cholesterol to plant,
fungal, and disease-associated sterols and comparison of sphingomyelin,
cerebrosides, and ceramide. J. Biol. Chem. 276, 33540-33546.
Yang, T., Li, S., Xu, H., Walsh, D. M. and Selkoe, D. J. (2017). Large soluble
oligomers of amyloid β-protein from Alzheimer brain are far less neuroactive than
the smaller oligomers to which they dissociate. J. Neurosci. 37, 152-163.
Zhu, D., Lai, Y., Shelat, P. B., Hu, C., Sun, G. Y. and Lee, J. C.-M. (2006).
Phospholipases A2 mediate amyloid-β peptide-induced mitochondrial
dysfunction. J. Neurosci. 26, 11111-11119.
11
RESEARCH ARTICLE Journal of Cell Science (2018) 131, jcs211789. doi:10.1242/jcs.211789
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
